样式: 排序: IF: - GO 导出 标记为已读
-
Paraneoplastic gastrointestinal dysmotility due to non-Hodgkin diffuse large B cell lymphoma: a case report. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-12 Emily Nash, John D Chetwood, Aravind G Tamilarasan, Emilia Prakoso
Paraneoplastic gastrointestinal dysmotility is a rare entity which occurs in association with malignancy. We present the second case associated with lymphoma, characterised by generalised gastrointestinal dysmotility with constipation, malnutrition, weight loss, and capsule endoscope retention. This case highlights the importance of maintaining a high index of suspicion for malignancy in patients with
-
Fatigue, depression, and sleep disorders are more prevalent in patients with metabolic-associated fatty liver diseases. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-12 Alaa M Mostafa, Shaimaa Moustafa Hafez, Noha M Abdullah, Yasser Fouad
To determine the prevalence and risk factors for depression, sleep disturbances, and exhaustion in MAFLD patients.
-
Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-12 Theodore Rokkas, Javier P Gisbert, Konstantinos Ekmektzoglou, Themistocles Dassopoulos, Yaron Niv, Colm O'Morain
Βiologic agents and small molecules have expanded the therapeutic armamentarium of moderate to severe ulcerative colitis (UC). However, their comparative efficacy and safety performance as maintenance treatments have not been sufficiently explored. We performed a systematic review and network meta-analysis (NWM) to assess the comparative efficacy and safety of all approved and emerging treatments for
-
Clinical outcomes with metformin use in diabetic patients with compensated cirrhosis: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Spyros Peppas, Stavros Doumas, Advait Suvarnakar, Jiling Chou, Ayah Arafat, Akram I Ahmad, James H Lewis
Previous studies have demonstrated a beneficial effect of metformin in patients with cirrhosis, but no improvement in liver histology.
-
High antibiotic resistance rates in Helicobacter pylori strains in Turkey over 20 years: implications for gastric disease treatment. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Burak Sarikaya, Riza Aytaç Çetinkaya, Derya Özyiğitoğlu, Sinem Akkaya Işik, Mustafa Kaplan, Duygu Kirkik, Levent Görenek
Helicobacter pylori (Hp) eradication therapy is crucial for preventing the development of gastritis, peptic ulcers, and gastric cancer. An increase in resistance against antibiotics used in the eradication of Hp is remarkable. This meta-analysis aims to examine the resistance rates of Hp strains isolated in Turkey over the last 20 years against clarithromycin (CLR), metronidazole (MTZ), levofloxacin
-
Sugar-sweetened beverage intake and long-term mortality in individuals with metabolic dysfunction-associated steatotic liver disease: a longitudinal analysis of the National Health and Nutrition Examination Survey database. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Ji Zhou, Chu Liu, Lili Liu, Lei Li
Consuming sugar-sweetened beverages (SSBs) has been linked to the development of various adverse health conditions, including metabolic dysfunction-associated steatotic liver disease (MASLD). This study evaluated associations between SSB intake and long-term mortality among individuals with MASLD using a nationally representative database.
-
Idiopathic chronic intestinal pseudo-obstruction syndrome is strongly associated with low serum levels of vitamin D. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Alba Panarese, Elton Dajti, Leonardo Henry Eusebi, Amanda Vestito, Rocco Maurizio Zagari
Idiopathic chronic intestinal pseudo-obstruction (CIPO) is associated with intestinal inflammation and malabsorption and may cause serum vitamin D deficiency. We aimed to assess whether there is an association between idiopathic CIPO and serum levels of 25-hydroxy-vitamin D. Consecutive patients with confirmed diagnosis of idiopathic CIPO were prospectively enrolled and matched with healthy controls
-
Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12-79 years. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Tsung-Hua Shen, Chung-Hsuen Wu, Yuan-Wen Lee, Chun-Chao Chang
Clinical observation revealed an increase in metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence among adults and adolescents and young adults (AYA). However, its prevalence trend in specific subgroups and its characteristics are unclear.
-
The influence of carvedilol posology timing on clinically significant portal hypertension: insights from elastography measurements. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Bruno Besteiro, Manuel Marques da Cruz, Cláudia Alves, Fátima Costa, Mariana Nunes, Daniel Martinho Dias, Ana Barreira, Joana Calvão, Mónica Mesquita, Sónia Carvalho, Inês Pinho, Paulo Carrola, José Presa Ramos
Carvedilol has emerged as the preferred β-blocker for treating portal hypertension. However, there is still a debate in dosing regimen, with a potential lower bioavailability in once-daily regimens. The aim of this study is to assess the acute effects of carvedilol posology in patients with clinically significant portal hypertension (CSPH), as a surrogate marker of bioavailability.
-
The frequency and clinical significance of antibodies to soluble liver antigen/liver pancreas in autoimmune hepatitis: a prospective single-center study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-04 Osman Yüksekyayla, Nabi Kina, Arjen Ulaba, Mehmet Emin Ergün, Ersin Batibay, Cem Şimşek, Fadile Yildiz Zeyrek, Staffan Wahlin, Cumali Efe
Soluble liver antigen/liver pancreas antibodies (anti-SLA/LP) are specific markers for autoimmune hepatitis (AIH) that have been associated with a distinct clinical phenotype and a more aggressive form of AIH. We prospectively evaluated the frequency and clinical significance of anti-SLA/LP in Turkish patients with AIH.
-
Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-04 Hisao Imai, Yukiyoshi Fujita, Eriko Hiruta, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Teruhiko Kamiya, Mitsuru Sandoh, Satoshi Takei, Kazuya Arai, Hiromi Nishiba, Junnosuke Mogi, Shiro Koizuka, Taeko Saito, Kyoko Obayashi, Kyoichi Kaira, Koichi Minato
Opioids are pain relievers that are often associated with opioid-induced constipation (OIC) that worsens with age. We performed a multicenter, retrospective analysis on the efficacy and safety of naldemedine, an opioid receptor antagonist, in treating OIC in patients with cancer (age >75 years).
-
Time trends in liver cancer mortality rates in Montenegro from 1990 to 2018. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-04 Mirjana Nedović Vuković, Marina Jakšić, Danijela Stojanović, Brigita Smolović
Liver cancer is the third most common cause of cancer-related deaths worldwide. Hepatitis B and C infections are the main factors affecting mortality. During recent years, Montenegro conducted activities on eradication of viral hepatitis according to the global strategy for the primary prevention of liver cancer mortality. The objective of this study was to assess the liver cancer mortality trend in
-
Referral for liver transplant following acute variceal bleeding: a multicenter cohort study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-04 Sofia Bragança, Marta Ramos, Sara Lopes, Gonçalo Alexandrino, Milena Mendes, Rui Perdigoto, João Coimbra, Hugo P Marques, Filipe S Cardoso
Referral for liver transplant (LT) following acute variceal bleeding (AVB) varies widely. We aimed to characterize and assess its impact on clinical outcomes.
-
Iron therapy supplementation in inflammatory bowel disease patients with iron deficiency anemia: findings from a real-world analysis in Italy. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-01 Gionata Fiorino, Jean-Frederic Colombel, Kostas Katsanos, Fermín Mearin, Jürgen Stein, Margherita Andretta, Stefania Antonacci, Loredana Arenare, Rita Citraro, Stefania Dell'Orco, Luca Degli Esposti, Antonio Ramirez de Arellano Serna, Neige Teldja Morin, Ioannis E Koutroubakis
This real-world analysis evaluated iron therapy supplementation in inflammatory bowel disease patients with iron-deficiency anemia, considering disease progression and healthcare resource consumption.
-
Myosteatosis is an independent risk factor for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunting. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-29 Wenfeng Shi, Hua Yin, Zhijian Yu, Yong Li, Xiao Bai, Sirui Fu, Chongyang Duan, Weiguo Xu, Yang Yang
The relationship between skeletal muscle and adipose tissue compositions and risk of overt hepatic encephalopathy (OHE) following transjugular intrahepatic portosystemic shunt (TIPS) treatment needs to be investigated.
-
Diverticulosis morphology is associated with risk of diverticulitis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-28 Miriam J Levy, Rebecca L Osterkamp, Kristof Glauninger, Lisa L Strate
The size, number and distribution of diverticula vary greatly in patients with diverticulosis. We aimed to study the association between the morphology of diverticulosis assessed on colonoscopy and the risk of diverticulitis. We performed a retrospective, case-control study of cases with a history of diverticulitis and controls with diverticulosis without diverticulitis matched on sex, age (within
-
Second-look upper endoscopy as the initial approach to subepithelial lesions: a reassuring and reliable strategy. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-28 Tiago Lima Capela, Vítor Macedo Silva, Marta Freitas, Tiago Cúrdia Gonçalves, Francisca Dias de Castro, Joana Magalhães, Sílvia Leite, José Cotter
Although endoscopic ultrasound (EUS) plays a critical role in the management of subepithelial lesions (SEL) of upper gastrointestinal tract many can be classified solely by a thorough upper gastrointestinal endoscopy (UGE) which can reduce the burden of additional studies.
-
Association between fecal short-chain fatty acid levels and constipation severity in subjects with slow transit constipation. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-28 Qi Chen, Die Chen, Xiangyue Gao, Ya Jiang, Ting Yu, Liuqin Jiang, Yurong Tang
We measured the fecal levels of short-chain fatty acids (SCFAs) in subjects with slow transit constipation (STC) and assessed the correlation between SCFA levels and disease severity as well as quality of life.
-
Prediction and evaluation of a nomogram model for recurrent acute pancreatitis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-26 Yuan Chen, Shu Huang, Bei Luo, Jiao Jiang, Wensen Ren, Kang Zou, Xiaolin Zhong, Muhan Lü, Xiaowei Tang
The purpose of this study was to investigate the influencing factors for recurrent acute pancreatitis and construct the nomogram model to predict the risk of recurrent acute pancreatitis.
-
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet's disease. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
Behçet's disease (BD) and nonalcoholic fatty liver disease (NAFLD) are chronic inflammatory diseases that share pathogenetic mechanisms. In this study, we investigated whether NAFLD influences the clinical outcomes in patients with intestinal BD.
-
Optimizing surveillance of low-risk metabolic dysfunction associated steatotic liver disease using transient elastography. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Harish Gopalakrishna, Gayatri B Nair, Roham Salman Roghani, Natarajan Ravendhran, Yaron Rotman
Most people with metabolic dysfunction-associated steatotic liver disease (MASLD) lack significant fibrosis and are considered low-risk. Surveillance strategy for low-risk MASLD remains uncertain.
-
Evaluation of chronic hepatitis B patients who voluntarily discontinued oral antiviral therapy: is there an answer to the controversial topic? Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Eyüp Arslan, Yeşim Yildiz, Ömer Karaşahin, Yakup Demir, Çiğdem Tümbül Mermutluoğlu, Gülten Ünlü, Ferit Kuşçu, Şafak Kaya, Fethiye Akgül, Tuba Damar Çakirca, Fatma Yilmaz Karadağ, Sibel Altunişik Toplu, Selçuk Nazik, İrem Akdemir, Şafak Özer Balin, Fatma Özlem Kandemir, Dilara İnan, Yaşar Bayindir, Yeşim Taşova, Mustafa Kemal Çelen
The uncertain treatment duration for nucleos(t)ide analogues (NA) used in the treatment of chronic hepatitis B (CHB) is an important problem for both patients and physicians. The aim of this study was to evaluate the determinants of virologic relapse (VR) and the optimum time of treatment discontinuation in the follow-up of CHB patients who voluntarily discontinued treatment after virological suppression
-
Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Yusuke Johira, Takashi Nakahara, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka
This study aimed to clarify the population in whom the presence of metabolic dysfunction-associated fatty liver disease (MAFLD) especially contributes to recurrence after liver resection for non-B, non-C hepatocellular carcinoma (NBNC-HCC).
-
Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Mohamed T Abuelazm, Islam Mohamed, Ahmed Naeem, Yehya Khlidj, Mohammad Tanashat, Basant E Katamesh, Husam Abusuilik, Obieda Altobaishat, Mohamed Abdelnabi, Basel Abdelazeem
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder characterized by excessive hepatic fat accumulation. Intermittent fasting (IF) has emerged as a potential therapeutic strategy with the ability to induce weight loss, improve insulin sensitivity and reduce hepatic steatosis. We aim to compare the efficacy of different IF regimens for MASLD management
-
Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Wasit Wongtrakul, Natthinee Charatcharoenwitthaya, Phunchai Charatcharoenwitthaya
The systematic review aimed to assess the risks of metabolic dysfunction-associated steatotic liver disease (MASLD) on all-cause and cause-specific mortality in patients with type 2 diabetes (T2DM). EMBASE and MEDLINE were searched from inception to June 2022 for observational studies examining the relationship between MASLD and the risk of mortality among T2DM patients. Meta-analysis was conducted
-
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-21 Geert D'Haens, Filip Baert, Silvio Danese, Taku Kobayashi, Edward V Loftus, William J Sandborn, Quentin Dornic, Dirk Lindner, Krisztina Kisfalvi, Ed G Marins, Séverine Vermeire
Vedolizumab is an anti-α4β7 integrin antibody used to treat moderate to severe ulcerative colitis (UC) and Crohn's disease (CD). This post hoc analysis of patient-reported outcomes (PROs) from the VISIBLE 1 (NCT02611830) and 2 (NCT02611817) phase 3 studies evaluated onset of treatment effect on patient-reported symptoms during 6-week vedolizumab induction.
-
The perioperative experience and needs of hepatocellular carcinoma patients in interventional therapy: a phenomenological qualitative study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-21 Ling Li, Hua-Zhen Zhang, Yan Ge, Ya-Li Rao, Ting Liu, Miao-Miao Guo, Shu-Ping Xiao
This study aims to investigate the perioperative experience and needs of patients with liver cancer for interventional therapy, in order to provide the basis for further improving a patient's medical experience and satisfaction.
-
Performance assessment of a new G12/A1 antibody-based rapid ELISA using commercially available and gluten-spiked food samples. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-21 Anil K Verma, Chiara Monachesi, Giulia N Catassi, Elisa Franceschini, Simona Gatti, Elena Lionetti, Carlo Catassi
Food products with <20 mg/kg gluten can be labeled 'gluten-free' according to international regulations. Several antibodies-based ELISAs have been develop to track gluten traces in food products. Among them, R5 and G12 antibody-based ELISAs are the frequently used methods. However, these antibodies have certain limitations. We evaluated the accuracy of G12/A1 antibody-based 'Glutentox ELISA Rapid G12'
-
Can quantitative surface antigen levels and systemic immune-inflammation index be predictive as a new indicator for the initiation of treatment in chronic hepatitis b? Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-21 Mehmet Koroglu, Muhammed Ali Ayvaz, Suat Baran Bakan, Abdullatif Sirin, Umit Akyuz
The natural history of chronic HBV infection (CHB) is generally divided into four phases: HBeAg-positive chronic HBV infection (EPCI) and -hepatitis (EPCH), HBeAg-negative chronic HBV infection (ENCI) and -hepatitis (ENCH). This study aimed to investigate changes in serum quantitative surface antigen (qHBsAg), systemic immune-inflammation index (SII) and systemic inflammatory response index (SIRI)
-
Osteonecrosis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-21 Himanshu Bhayana, Tarun Kumar Sharma, Alka Sharma, Mehtab S Dhillon, Anuraag Jena, Deepak Kumar, Vishal Sharma
The relationship of inflammatory bowel disease (IBD) with osteonecrosis or avascular necrosis (AVN) is uncertain.
-
Prevalence and risk factors for cirrhotic cardiomyopathy: a prospective cross-sectional study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-16 Huawei Xu, Yu Zhang, Yanjing Gao
This study aimed to assess cardiac structure and function in patients with cirrhosis, to investigate the prevalence of cirrhotic cardiomyopathy (CCM) in patients with cirrhosis of different etiologies and to analyze the risk factors for the development of CCM.
-
Renal dysfunction during treatment of chronic hepatitis B with tenofovir disoproxyl fumarate and associated risk factors. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-16 Alessandra M de A Maciel, Maria Lucia C G Ferraz, Renata de M Perez, Carlos Eduardo Brandão-Mello
To analyze the evolution of glomerular filtration rate (GFR) and the presence of renal tubular dysfunction during the treatment of chronic hepatitis B virus (HBV) infection with tenofovir disoproxil fumarate (TDF) and to determine the risk factors involved.
-
The role of donor sex on the post-liver transplant outcomes in patients with primary sclerosing cholangitis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-16 David Uihwan Lee, Ashton Harmacinski, Sindhura Kolachana, Aneesh Bahadur, KeeSeok Lee, Ki Jung Lee, Alex Pu, Harrison Chou, Gregory Hongyuan Fan, Raza Malik
Primary sclerosing cholangitis (PSC) can result in hepatic decompensation and require liver transplantation (LT). This study investigates the effect of the sex of the donor and recipient as a prognostic risk factor for adverse outcomes after LT in patients with PSC.
-
Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-16 Yaqing Bai, Yinghao Sun, Qi He, Xiaoyin Bai, Hong Yang
Ustekinumab has two alternative drug maintenance intervals for inflammatory bowel disease (IBD), every 8 weeks (Q8W) and every 12 weeks (Q12W). The current study aimed at evaluating the comparative efficacy and safety of the two maintenance intervals in patients with IBD. A systematic search on PubMed, Web of Science, Cochrane Library, and EMBASE was carried out. The relative risk (RR) was pooled for
-
Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-01-31 Tamara Mogilevski, Anke L Nguyen, Mary Ajamian, Rebecca Smith, Sam Rosella, Miles P Sparrow, Gregory T Moore, Peter R Gibson
Inflammatory bowel disease (IBD) is associated with chronic intestinal barrier dysfunction, though its non-invasive assessment remains challenging. This study aimed to determine how four putative circulating markers vary across differing states of intestinal inflammation and with therapy in patients with IBD.
-
Variation in proliferative and cell cycle markers in Barrett's esophagus in relation to circumferential and axial location in the esophagus. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-01-22 Nosheen Umar, Lance Alleyne, Danny Cheung, James Rees, Caitlin Trudgill, Ulises Zanetto, Suhail Muzaffar, Nigel Trudgill
Adenocarcinoma in Barrett's esophagus (BE) occurs more frequently between 12 and 3 o'clock at the gastroesophageal junction (GEJ).
-
Unraveling the blood microbiome: novel insights into inflammasome responses in Crohn's disease. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-01-22 Duygu Kirkik, Sevgi Kalkanli Tas, Alpaslan Tanoglu
Crohn's disease (CD), an inflammatory bowel disease with unknown etiology, is influenced by genetic, environmental, and immunological factors. This study aimed to analyze the blood microbiome and inflammasome responses, emphasizing NLRP3 protein expression and IL-1β and IL-18 plasma levels, between Crohn's patients and healthy subjects.
-
Late presentation for hepatitis C treatment: prevalence and risk factors in the Swiss Hepatitis C Cohort. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-01-22 Nathalie Brunner, Thomas Grischott, Philip Bruggmann
Patients with 'late presentation' (LP) of chronic hepatitis C infection (HCV) have already developed advanced liver disease before receiving direct-acting antiviral (DAA) treatment. Even after successful treatment, the risk of morbidity and premature death remains elevated, leading to an unnecessary disease burden. This study aimed to assess the prevalence of LP within the prospective observational
-
AST to ALT ratio as a prospective risk predictor for liver cirrhosis in patients with chronic HBV infection. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-01-22 Xiaohuan Lai, Haiyan Chen, Xiaofeng Dong, Guanlin Zhou, Dong Liang, Fei Xu, Hongxia Liu, Yingmin Luo, Hui Liu, Shaogui Wan
Serum aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR) is one of the most frequent indicators to discriminate fibrosis and cirrhosis. However, the results remained controversial. The aim of this study was to evaluate the predictive effect of AAR on hepatitis B virus (HBV)-related cirrhosis development.
-
Endoscopy in pediatric polyposis syndromes: why, when and how. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-01-10 Shlomi Cohen, Warren Hyer, Thomas Attard
Single or multiple polyps are frequently encountered during colonoscopy among children and adolescents and may be indicative of hereditary polyposis syndrome (HPS). The management of children with single or multiple polyps is guided by the number of polyps, their distribution and the histological findings. Children with HPS carry a high risk of complications, including intestinal and extra-intestinal
-
Predictors and impact of aspiration pneumonia in patients undergoing esophagogastroduodenoscopy: national inpatient sample 2016-2020. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-27 Jay Patel, Aalam Sohal, Hunza Chaudhry, Shivam Kalra, Isha Kohli, Ishandeep Singh, Dino Dukovic, Juliana Yang
Aspiration pneumonia is a rare but feared complication among patients undergoing esophagogastroduodenoscopy (EGD). Our study aims to assess the incidence as well as risk factors for aspiration pneumonia in patients undergoing EGD.
-
Exploration of useful clinical laboratory values as diagnostic criteria for eosinophilic gastroenteritis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-27 Takashi Kobayashi, Takahiro Hayashi, Aya Torii-Goto, Mina Aoyagi, Takako Ichinose, Yukako Okada, Noriyasu Senda, Yoshiaki Katano
Eosinophilic gastroenteritis (EGE) is a rare eosinophilic infiltrative disorder. In Japan, EGE is diagnosed using clinical symptoms as well as microscopic, haematologic and histopathological findings. In this study, we examined the usefulness of laboratory data in the diagnosis of EGE.
-
Patients with early-stage alcohol-associated liver disease are at increased risk of hospital readmission and death. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-27 Mahmoud Aryan, Steve Qian, Zhiguo Chen, Jeremy Louissaint, Xia Qian, Russell Rosenblatt, Elizabeth Verna, Robert Brown, Robert Wong, Virginia Clark, Wei Zhang
Patients with alcohol use disorder (AUD) can develop alcohol-associated fatty liver disease (AFLD). However, the impact of AFLD on outcomes remains unclear. We studied the impact of AFLD on readmission, 30-day mortality, and overall mortality in patients admitted with AUD.
-
Anal defecatory function in ulcerative colitis patients after total proctocolectomy and ileal pouch-anal anastomosis: a prospective cohort study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-27 Nikos Viazis, Anastasios Manolakis, Marina Vraka, Iordanis Mylonas, Emmanuela Tsoukali, George Karamanolis, Gerasimos J Mantzaris, Ioannis Papakonstantinou
Total proctocolectomy (TPC) followed by ileal pouch-anal anastomosis (IPAA) remains the only viable option whenever different treatment modalities fail in patients with ulcerative colitis (UC).
-
Advanced chronic renal disease is an independent risk factor for inpatient mortality following transjugular intrahepatic portosystemic shunt procedure. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-27 Renxi Li, Shawn Sarin
Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure used to alleviate portal hypertension in patients with decompensated liver cirrhosis. However, the risks and outcomes associated with TIPS in patients with advanced chronic kidney disease (CKD) remain uncertain. This study aimed to investigate the perioperative outcomes of TIPS procedures in patients with advanced CKD using the National
-
Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-27 Gerassimos J Mantzaris, Brian Bressler, Shashi Adsul, Michelle Luo, Chris Colby, Neil R Brett, Sumit Saha, Pravin Kamble, Song Wang, Andres Yarur
This study compared the real-world effectiveness and safety of α4β7-integrin inhibitor vedolizumab and anti-tumor necrosis factor alpha (anti-TNFα) inhibitor infliximab in biologic-naive patients with Crohn's disease (CD).
-
Gastric juice analysis in clinical practice: why, how, and when. The experience with EndoFaster. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-27 Angelo Zullo, Bruno Annibale, Mario Dinis-Ribeiro, Gianluca Fanchellucci, Gianluca Esposito, Cesare Hassan
Gastric juice analysis may be useful for clinical purposes, including the detection of H. pylori infection and diffuse atrophic gastritis on gastric mucosa. EndoFaster is a novel device which performs real-time analysis of gastric juice revealing the infection and hypochlorhydria by measuring ammonium concentrations and pH levels. This review aimed to evaluate the clinical applications of such a tool
-
A bidirectional two-sample Mendelian randomization using the gut microbiota to reveal potential therapeutic targets for primary sclerosing cholangitis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-11 Xiru Liang, Ziwei Wang, Qiuai Shu, Xindi Huang, Jinhai Wang, Jian Wu, Na Liu, Ning Xie
Previous studies indicate that gut microbiota correlates to primary sclerosing cholangitis (PSC), but the causation is still unclear. We sought to reveal the causal relationship between gut microbiota and PSC with a bidirectional two-sample Mendelian randomization (MR) analysis.
-
Effectiveness and prognosis of covered stents with different diameters in transjugular intrahepatic portosystemic shunt: a meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-11 Jiahong Gong, Ziqin Xia, Zhidai Zhou, Liping Chen, Xiaobing Wang, Feng Zhou
This meta-analysis was designed to evaluate the clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) conducted utilizing stents of different diameters, thus providing recommendations for more logical selections of covered stents for patients with portal hypertension, in particular for the Asian population.
-
Basal cortisol levels do not predict adrenal responsiveness in acute decompensated cirrhosis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-11 Brian J Wentworth, Matthew Schliep, Wendy M Novicoff, Zachary H Henry, Helmy M Siragy
Morning total cortisol (TC) levels have been shown to predict adrenal dysfunction (AD) in the general population, but their utility in cirrhosis is unknown.
-
The performance of hepatitis B surface antigen quantification as a noninvasive biomarker predicting liver injury and serum hepatitis B virus DNA level. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-11 Madina Abdullayeva, Muammer Çelik, Ziya Kuruüzüm
Chronic hepatitis B (CHB) is still a major public health problem worldwide. Recently, evidence indicating that serum hepatitis B surface antigen (HBsAg) quantification can be used for monitorization of hepatitis B virus (HBV) infection has been increased. In this study, we evaluated HBsAg levels during the natural course of CHB and identified correlations between HBsAg, HBV DNA levels and liver histopathology
-
Endoscopic full-thickness resection vs. endoscopic submucosal dissection of residual/recurrent colonic lesions on scars: a retrospective Italian and Japanese comparative study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-12-01 Federico Barbaro, Luigi Giovanni Papparella, Michele Francesco Chiappetta, Cristina Ciuffini, Takehide Fukuchi, Jun Hamanaka, Giuseppe Quero, Silvia Pecere, Giulia Gibiino, Lucio Petruzziello, Shin Maeda, Kingo Hirasawa, Guido Costamagna
Endoscopic treatment of recurrent/residual colonic lesions on scars is a challenging procedure. In this setting, endoscopic submucosal dissection (ESD) is considered the first choice, despite a significant rate of complications. Endoscopic full-thickness resection (eFTR) has been shown to be well-tolerated and effective for these lesions. The aim of this study is to conduct a comparison of outcomes
-
Interaction between dietary flavonoid intake and trouble sleeping on non-alcoholic fatty liver disease risk: a cross-sectional study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-11-30 Xinxia Yang, Shitu Zhuo, Taiyong Fang
The possible interaction of dietary flavonoid intake and sleep on non-alcoholic fatty liver disease (NAFLD) has not been well studied. This study investigated the interaction between dietary flavonoid intake and trouble sleeping on the risk of NAFLD.
-
Circulating immune signatures across clinical stages of chronic pancreatitis: a pilot study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-11-30 Rasmus Hagn-Meincke, Phil A Hart, Dana K Andersen, Santhi S Vege, Evan L Fogel, Jose Serrano, Melena D Bellin, Mark D Topazian, Darwin L Conwell, Liang Li, Stephen K Van Den Eeden, Asbjørn M Drewes, Stephen J Pandol, Chris E Forsmark, William E Fisher, Dhiraj Yadav, Søren S Olesen, Walter G Park
This pilot study seeks to identify serum immune signatures across clinical stages of patients with chronic pancreatitis (CP).
-
Association between novel inflammatory markers and non-alcoholic fatty liver disease: a cross-sectional study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-11-30 Gang Wang, Yu Zhao, Zeya Li, Dan Li, Feng Zhao, Jing Hao, Chunlei Yang, Jiashu Song, Xianzhong Gu, Rongchong Huang
This study aimed to investigate the association between novel inflammatory markers (NIMs) and non-alcoholic fatty liver disease (NAFLD).
-
The incidence and predisposing factors for irritable bowel syndrome following COVID-19: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-11-30 Yi-Nuo Wang, Li-Ying Zhou, Yu-Hong Huang, Min Jiang, Cong Dai
Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder. Several studies have analyzed the long-term GI symptoms and IBS following coronavirus disease 2019 (COVID-19). The purpose of this study is to evaluate the incidence and predisposing factors for IBS following COVID-19 by a systematic review and meta-analysis.
-
Association of BMI with mortality in drug-induced liver injury. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-11-30 Zikun Ma, Min Li, Yan Wang, Cailun Zou, Yu Wang, Tiantian Guo, Yu Su, Mengmeng Zhang, Yao Meng, Jidong Jia, Jing Zhang, Zhengsheng Zou, Xinyan Zhao
To clarify the associations between BMI and the incidences of all-cause death or liver-related death (LRD)/liver transplantation (LT) in drug-induced liver injury (DILI).
-
Determination and prospective validation of cut-off values for the diagnosis of liver cirrhosis for point shear-wave elastography/acoustic radiation force impulse imaging using the ACUSON Sequoia ultrasound system. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-11-21 B Meitner-Schellhaas, S Schüler, T Vogl, D Jesper, M Vetter, M Waldner, D Strobel
Point shear-wave elastography (pSWE) alias acoustic radiation force impulse (ARFI) imaging is a well-established ultrasound-based technique for the non-invasive assessment of liver tissue stiffness. As cut-off values for liver cirrhosis cannot be transferred from one ultrasound system to another, this study aimed at determining cut-off values for the newly developed Siemens ACUSON Sequoia ultrasound
-
Combined gastric and colorectal cancer endoscopic screening may be cost-effective in Europe with the implementation of artificial intelligence: an economic evaluation. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-11-15 Diogo Libanio, Giulio Antonelli, Fleur Marijnissen, Maanon Cw Spaander, Cesare Hassan, Mario Dinis-Ribeiro, Miguel Areia
Endoscopic screening for gastric cancer (GC) is not recommended in low-intermediate incidence countries. Artificial intelligence (AI) has high accuracy in GC detection and might increase the cost-effectiveness of screening strategies. We aimed to assess the cost-effectiveness of AI for GC detection in settings with different GC incidence and different accuracies of AI systems.
-
Thromboelastography characteristics in critically ill patients with liver disease. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2023-11-15 Ramanpreet K Bajwa, Cerise Kleb, Muhammad Salman Faisal, Muhammad Zarrar Khan, Afshin Khan, Ruishen Lyu, Dana Angelini, Omar T Sims, Jamak Modaresi Esfeh
The purpose of this study was to determine how thromboelastography (TEG) parameters differ by various clinical conditions that commonly occur in patients with cirrhosis, including sepsis, acute on chronic liver failure (ACLF), alcohol-associated hepatitis (AAH) and portal vein thrombosis (PVT).